Sarepta Therapeutics Inc (SRPT)
129.86
+5.41
(+4.35%)
USD |
NASDAQ |
May 31, 16:00
130.10
+0.24
(+0.18%)
Pre-Market: 20:00
Sarepta Therapeutics Research and Development Expense (Annual): 877.39M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 877.39M |
| December 31, 2022 | 877.09M |
| December 31, 2021 | 771.18M |
| December 31, 2020 | 722.34M |
| December 31, 2019 | 560.91M |
| December 31, 2018 | 401.84M |
| December 31, 2017 | 166.71M |
| December 31, 2016 | 188.27M |
| December 31, 2015 | 146.39M |
| December 31, 2014 | 94.23M |
| December 31, 2013 | 72.91M |
| December 31, 2012 | 52.40M |
| December 31, 2011 | 66.86M |
| December 31, 2010 | 35.97M |
| Date | Value |
|---|---|
| December 31, 2009 | 24.40M |
| December 31, 2008 | 27.33M |
| December 31, 2007 | 34.76M |
| December 31, 2006 | 25.35M |
| December 31, 2005 | 17.12M |
| December 31, 2004 | 20.74M |
| December 31, 2003 | 15.28M |
| December 31, 2002 | 22.41M |
| December 31, 2001 | 12.75M |
| December 31, 2000 | 9.268M |
| December 31, 1999 | 6.70M |
| December 31, 1998 | 6.30M |
| December 31, 1997 | 2.70M |
| December 31, 1996 | 1.70M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
560.91M
Minimum
2019
877.39M
Maximum
2023
761.78M
Average
771.18M
Median
2021
Research and Development Expense (Annual) Benchmarks
| PTC Therapeutics Inc | 666.56M |
| Johnson & Johnson | 15.08B |
| Regenxbio Inc | 232.27M |
| Shockwave Medical Inc | 145.65M |
| Catalyst Pharmaceuticals Inc | 93.15M |